EXTH-76. (1)H AND HYPERPOLARIZED (13)C MRS BIOMARKERS OF IDH1 MUTANT GLIOMA RESPONSE TO TEMOZOLOMIDE THERAPY

The alkylating agent temozolomide (TMZ), previously reserved for treatment of glioblastoma, is now being considered for the treatment of low-grade glioma that are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene. Though the treatment of IDH1 mutant patients with TMZ improves surviva...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Subramani, Elavarasan, Najac, Chloe, Batsios, Georgios, Viswanath, Pavithra, Radoul, Marina, Gillespie, Anne Marie, Pieper, Russell, Ronen, Sabrina
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216354/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.423
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak